Cargando…

Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants

Immunization with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has greatly reduced coronavirus disease 2019 (COVID-19)-related deaths and hospitalizations, but waning immunity and the emergence of variants capable of immune escape indicate the need for novel SARS-CoV-2 vacci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beavis, Ashley C., Li, Zhuo, Briggs, Kelsey, Huertas-Díaz, María Cristina, Wrobel, Elizabeth R., Najera, Maria, An, Dong, Orr-Burks, Nichole, Murray, Jackelyn, Patil, Preetish, Huang, Jiachen, Mousa, Jarrod, Hao, Linhui, Hsiang, Tien-Ying, Gale, Michael, Harvey, Stephen B., Tompkins, S. Mark, Hogan, Robert Jeffrey, Lafontaine, Eric R., Jin, Hong, He, Biao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196109/ https://www.ncbi.nlm.nih.gov/pubmed/35702147 http://dx.doi.org/10.1101/2022.06.07.495215

Ejemplares similares

Intranasal parainfluenza virus type 5 (PIV5)–vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study
por: Spearman, Paul, et al.
Publicado: (2023)

A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted Borrelia burgdorferi in mice
por: Gingerich, Maria Cristina, et al.
Publicado: (2023)

Structure of the Parainfluenza Virus 5 (PIV5) Hemagglutinin-Neuraminidase (HN) Ectodomain
por: Welch, Brett D., et al.
Publicado: (2013)

1104. Characteristics and Seasonality of Children Hospitalized with Parainfluenza Virus Infections (PIV), including PIV-4, New Vaccine Surveillance Network, 2016–2020
por: de St. Maurice, Annabelle M, et al.
Publicado: (2023)

Efficacy of a Parainfluenza Virus 5 (PIV5)-Based H7N9 Vaccine in Mice and Guinea Pigs: Antibody Titer towards HA Was Not a Good Indicator for Protection
por: Li, Zhuo, et al.
Publicado: (2015)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
por: Beavis, Ashley C., et al.
Publicado: (2023)

Evaluating a Parainfluenza Virus 5-Based Vaccine in a Host with Pre-Existing Immunity against Parainfluenza Virus 5
por: Chen, Zhenhai, et al.
Publicado: (2012)

Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys
por: Le Nouën, Cyril, et al.
Publicado: (2022)

Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques
por: Nouën, Cyril Le, et al.
Publicado: (2022)

A novel parainfluenza virus type 3 (PIV3) identified from goat herds with respiratory diseases in eastern China
por: Li, Wenliang, et al.
Publicado: (2014)

Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge
por: Clark, Kimberly M., et al.
Publicado: (2011)

A universal mammalian vaccine cell line substrate
por: Murray, Jackelyn, et al.
Publicado: (2017)

PIV-37 Do viral respiratory co-pathogens contribute to morbidity & mortality in an outbreak of parainfluenza type 3 in haematology-oncology patients?
por: Sehmi, J.K., et al.
Publicado: (2009)

A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters
por: Liu, Xueqiao, et al.
Publicado: (2021)

Early Activation of the Innate Immunity and Specific Cellular Immune Pathways after Vaccination with a Live Intranasal Viral Vaccine and Challenge with Bovine Parainfluenza Type 3 Virus
por: Nuijten, Piet, et al.
Publicado: (2022)

Efficacy of a live intranasal vaccine against parainfluenza type 3 and bovine respiratory syncytial virus in young calves with maternally derived antibodies
por: Metcalfe, Lucy, et al.
Publicado: (2020)

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults
por: Scaggs Huang, Felicia, et al.
Publicado: (2020)

Gene-edited vero cells as rotavirus vaccine substrates
por: Orr-Burks, Nichole, et al.
Publicado: (2019)

Intranasally Administered Antigen 85B Gene Vaccine in Non-Replicating Human Parainfluenza Type 2 Virus Vector Ameliorates Mouse Atopic Dermatitis
por: Kitagawa, Hiroshi, et al.
Publicado: (2013)

Human immune responses elicited by an intranasal inactivated H5 influenza vaccine
por: Ainai, Akira, et al.
Publicado: (2020)

Immunohistochemistry analysis of pulmonary infiltrates in necropsy samples of children with non-pandemic lethal respiratory infections (RSV; ADV; PIV1; PIV2; PIV3; FLU A; FLU B)
por: de Souza Costa, Victor Horácio, et al.
Publicado: (2014)

2754. Phase 1 Trial of an mRNA-Based Combination Vaccine Against hMPV and PIV3
por: Shaw, Christine, et al.
Publicado: (2019)

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
por: Hasegawa, Hideki, et al.
Publicado: (2009)

Parainfluenza Virus 5 Infection in Neurological Disease and Encephalitis of Cattle
por: Hierweger, Melanie M., et al.
Publicado: (2020)

A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys
por: Tang, Roderick S., et al.
Publicado: (2005)

Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates
por: Liu, Xueqiao, et al.
Publicado: (2020)

Pressure from 2D snapshot PIV
por: Van der Kindere, J. W., et al.
Publicado: (2019)

Progress towards a Miniaturised PIV System
por: Özer, Özgün, et al.
Publicado: (2022)

Strategies for intranasal delivery of vaccines
por: Zaman, Mehfuz, et al.
Publicado: (2012)

Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates
por: Xiao, Peng, et al.
Publicado: (2021)

PLK1 Down-Regulates Parainfluenza Virus 5 Gene Expression
por: Sun, Dengyun, et al.
Publicado: (2009)

Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge
por: Mann, Alex J., et al.
Publicado: (2014)

Memorandum: request to reinstall PS185 in PIV/85
por: Kilian, K
Publicado: (1985)

Experimental research on intraocular aqueous flow by PIV method
por: Yang, Hongyu, et al.
Publicado: (2013)

Hemodynamic Study of a Patient-Specific Intracranial Aneurysm: Comparative Assessment of Tomographic PIV, Stereoscopic PIV, In Vivo MRI and Computational Fluid Dynamics
por: Wu, Xiaolin, et al.
Publicado: (2021)

Cytokines: The Future of Intranasal Vaccine Adjuvants
por: Thompson, Afton L., et al.
Publicado: (2011)

Intranasal COVID-19 vaccine: a modern vaccination approach
por: Shahnoor, Syeda, et al.
Publicado: (2023)

Intranasal Flu Vaccine Protective against Seasonal and H5N1 Avian Influenza Infections
por: Alsharifi, Mohammed, et al.
Publicado: (2009)

Development of improved vaccine cell lines against rotavirus
por: Wu, Weilin, et al.
Publicado: (2017)

Parainfluenza Virus 5 as Possible Cause of Severe Respiratory Disease in Calves, China
por: Liu, Ye, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mt7096lc8emvp8cdpouqad4771